CytoMed Therapeutics Ltd

GDTC

Company Profile

  • Business description

    CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

  • Contact

    1 Commonwealth Lane
    No. 08-22 One Commonwealth
    Singapore149544
    SGP

    T: +65 62507738

    https://w2.cytomed.sg

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    42

Stocks News & Analysis

stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks

This onetime AI market darling is now surprisingly undervalued

This AI leader qualifies as a GARP stock today.
stocks

Undervalued ASX miner hits production homerun

Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.0070.20-0.76%
CAC 408,509.6424.000.28%
DAX 4025,629.2417.210.07%
Dow JONES (US)52,485.03276.970.53%
FTSE 10010,868.0529.22-0.27%
HKSE25,884.4325.550.10%
NASDAQ25,373.85251.681.00%
Nikkei 22564,362.022,494.594.03%
NZX 50 Index13,699.2863.50-0.46%
S&P 5007,489.7252.090.70%
S&P/ASX 2008,976.8073.10-0.81%
SSE Composite Index3,832.2627.570.72%

Market Movers